胃印戒细胞癌患者[68Ga]Ga-FAPI与[18F]FDG摄取比较:一项多中心回顾性研究
该多中心回顾性研究纳入4个中心34例组织学确诊胃印戒细胞癌患者,比较[68Ga]Ga-FAPI与[18F]FDG PET的SUVmax、TBR及诊断准确性。FAPI在原发灶、淋巴结及骨和内脏转移中SUVmax和TBR均更高,对原发灶、局部复发、淋巴结转移和远处转移的敏感度也更高。作者认为结果支持[68Ga]Ga-FAPI用于胃印戒细胞癌诊断与分期。
要点
- 胃印戒细胞癌原发灶FAPI SUVmax 5.2高于FDG 2.2,TBR 7.6高于1.3。
- FAPI对原发灶敏感度73%(16/22)高于FDG 18%(4/22),p<0.001。
- FAPI对淋巴结转移敏感度77%(59/77)高于FDG 23%(18/77),p<0.001。
核心结论
- 多中心回顾性分析结果支持[68Ga]Ga-FAPI示踪剂用于胃印戒细胞癌的诊断和分期。
研究设计与样本
- 回顾性多中心分析,纳入4个医疗中心34例组织学确诊胃印戒细胞癌患者,分析27对PET/CT和7对PET/MRI扫描;采用Wilcoxon符号秩检验比较摄取,McNemar检验比较诊断准确性。
关键影像表现/征象
- 原发肿瘤中[68Ga]Ga-FAPI的SUVmax为5.2、TBR为7.6,[18F]FDG的SUVmax为2.2、TBR为1.3(SUVmax p=0.001;TBR p<0.001)。
- 受累淋巴结中[68Ga]Ga-FAPI的SUVmax为6.8、TBR为5.8,[18F]FDG的SUVmax为2.5、TBR为1.3(均p<0.001)。
- 骨和内脏转移中[68Ga]Ga-FAPI的SUVmax为6.5、TBR为6.3,[18F]FDG的SUVmax为2.4、TBR为1.3(均p<0.001)。
诊断标准与关键数值
- 原发肿瘤敏感度:[68Ga]Ga-FAPI 73%(16/22)vs [18F]FDG 18%(4/22),p<0.001。
- 局部复发敏感度:[68Ga]Ga-FAPI 100%(7/7)vs [18F]FDG 29%(2/7),p=0.071。
- 淋巴结转移敏感度:[68Ga]Ga-FAPI 77%(59/77)vs [18F]FDG 23%(18/77),p<0.001。
- 远处转移敏感度:[68Ga]Ga-FAPI 93%(207/222)vs [18F]FDG 39%(86/222),p<0.001。
临床应用与阅片要点
- 作者认为结果支持[68Ga]Ga-FAPI示踪剂用于胃印戒细胞癌的诊断和分期。
- 要点指出[68Ga]Ga-FAPI PET/CT是检测原发和转移性疾病有前景的影像方法,对胃印戒细胞癌TNM分期有参考意义。
- 多中心34例研究显示[68Ga]Ga-FAPI PET在检测原发/复发肿瘤和转移灶方面放射性示踪剂摄取、肿瘤-本底比及诊断准确性均高于[18F]FDG PET。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE: In this study, we investigated the role of [68Ga]Ga-FAPI PET imaging in the detection of primary and metastatic gastric signet-ring-cell carcinoma (GSRCC) and compared with [18F]FDG PET.
METHODS: This retrospective multicenter analysis included 34 patients with histologically confirmed GSRCCs from four medical centers. The maximum standard uptake value (SUVmax), tumor-to-background ratio (TBR), and diagnostic accuracy were compared between the two modalities. [18F]FDG and [68Ga]Ga-FAPI uptakes were compared by using the Wilcoxon signed-rank test. McNemar's test was used to compare the diagnostic accuracy between the two techniques.
RESULTS: Data were analyzed from 27 paired PET/CT and 7 paired PET/MRI scans for 34 GSRCC patients (16 men and 18 women) who had a median age of 51 years (range: 25-85 years). [68Ga]Ga-FAPI PET showed higher SUVmax and TBR values than did [18F]FDG PET in the primary tumors (SUVmax: 5.2 vs. 2.2, p = 0.001; TBR: 7.6 vs. 1.3, p < 0.001), involved lymph nodes (SUVmax: 6.8 vs. 2.5, p < 0.001; TBR: 5.8 vs. 1.3, p < 0.001), and bone and visceral metastases (SUVmax: 6.5 vs. 2.4, p < 0.001; TBR: 6.3 vs. 1.3, p < 0.001). In diagnostic performance, [68Ga]Ga-FAPI PET exhibited higher sensitivity than [18F]FDG PET for detecting primary tumors (73% [16/22] vs. 18% [4/22], p < 0.001), local recurrences (100% [7/7] vs. 29% [2/7], p = 0.071), lymph node metastases (77% [59/77] vs. 23% [18/77], p < 0.001), and distant metastases (93% [207/222] vs. 39% [86/222], p < 0.001).
CONCLUSION: The results from this multicenter retrospective analysis justify the clinical use of [68Ga]Ga-FAPI tracers for GSRCC diagnosis and staging.
KEY POINTS: • [68Ga]Ga-FAPI PET/CT is a promising imaging modality for the detection of primary and metastatic disease and has implications for TNM staging in GSRCC. • In this multicenter study of 34 patients with GSRCC, [68Ga]Ga-FAPI PET exhibited greater radiotracer uptake, tumor-to-background ratios, and diagnostic accuracy than [18F]FDG PET for detecting primary/recurrent tumors and metastatic lesions.
引用
- Chen H, Pang Y, Li J, et al. Comparison of [68Ga]Ga-FAPI and [18F]FDG uptake in patients with gastric signet-ring-cell carcinoma: a multicenter retrospective study. Eur Radiol. 2022. PMID: 35976396. doi:10.1007/s00330-022-09084-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。